114 related articles for article (PubMed ID: 15160756)
1. Contrast enhanced MR-guided biopsy of hepatocellular carcinoma.
König CW; Trübenbach J; Fritz J; Lauer UM; Claussen CD; Pereira PL
Abdom Imaging; 2004; 29(1):71-6. PubMed ID: 15160756
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
Grazioli L; Morana G; Caudana R; Benetti A; Portolani N; Talamini G; Colombari R; Pirovano G; Kirchin MA; Spinazzi A
Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
[TBL] [Abstract][Full Text] [Related]
4. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
5. [Hepatocyte targeted MR contrast agent--Gd-BOPTA(E-7155)].
Kuwatsuru R; Katayama H
Nihon Rinsho; 2001 Oct; 59 Suppl 6():323-7. PubMed ID: 11761966
[No Abstract] [Full Text] [Related]
6. MRI findings of rapidly progressive hepatocellular carcinoma.
Kierans AS; Leonardou P; Hayashi P; Brubaker LM; Elazzazi M; Shaikh F; Semelka RC
Magn Reson Imaging; 2010 Jul; 28(6):790-6. PubMed ID: 20427139
[TBL] [Abstract][Full Text] [Related]
7. MRI findings of hepatocellular carcinoma.
Wiwanitkit V
Magn Reson Imaging; 2011 Feb; 29(2):303. PubMed ID: 21129874
[No Abstract] [Full Text] [Related]
8. Magnetic resonance coronary angiography: comparison between a Gd-BOPTA- and a Gd-DTPA-enhanced spoiled gradient-echo sequence and a non-contrast-enhanced steady-state free-precession sequence.
Nassenstein K; Breuckmann F; Hunold P; Barkhausen J; Schlosser T
Acta Radiol; 2009 May; 50(4):406-11. PubMed ID: 19308763
[TBL] [Abstract][Full Text] [Related]
9. MultiHance: help or hype?
Bartolozzi C; Spinazzi A
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S151-9. PubMed ID: 10608411
[TBL] [Abstract][Full Text] [Related]
10. MR imaging of CNS tumors: are all contrast agents created the same?
Essig M
Neuroradiology; 2006 Apr; 48 Suppl 1():3-8. PubMed ID: 16699847
[TBL] [Abstract][Full Text] [Related]
11. Capsule of hepatocellular carcinoma: where and how does the capsule show enhancement?
Itai Y
Radiology; 1999 Feb; 210(2):577-9. PubMed ID: 10207449
[No Abstract] [Full Text] [Related]
12. [Early phase II trial of Gd-BOPTA (E7155) for the MR imaging of liver tumors].
Kuwatsuru R; Kadoya M; Tanimoto A; Hirohashi S; Katayama H
Nihon Igaku Hoshasen Gakkai Zasshi; 1996 Jul; 56(8):555-63. PubMed ID: 8797346
[TBL] [Abstract][Full Text] [Related]
13. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
[TBL] [Abstract][Full Text] [Related]
14. Initial experience on utility of gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted MR cholangiography in diagnosis of acute cholecystitis.
Akpinar E; Turkbey B; Karcaaltincaba M; Balli O; Akkapulu N; Balas S; Tirnaksiz B; Akata D; Akhan O
J Magn Reson Imaging; 2009 Sep; 30(3):578-85. PubMed ID: 19711404
[TBL] [Abstract][Full Text] [Related]
15. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
16. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
17. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths.
Yrjänä SK; Vaara T; Karttunen A; Koivukangas J
Invest Radiol; 2008 Apr; 43(4):267-75. PubMed ID: 18340251
[TBL] [Abstract][Full Text] [Related]
18. Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight.
Pastor CM
Radiology; 2010 Nov; 257(2):589. PubMed ID: 20959554
[No Abstract] [Full Text] [Related]
19. Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images.
Marin D; Iannaccone R; Catalano C; Passariello R
J Magn Reson Imaging; 2006 Sep; 24(3):690-4. PubMed ID: 16878304
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte-specific magnetic resonance imaging contrast agents.
Fidler J; Hough D
Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
